CAN008 is a glycosylation fusion protein that blocks the interaction between the CD95 receptor and its cognate ligand CD95L through binding to CD95L. It has a unique dual mechanism of action, through both inhibiting the invasive growth of tumor cells and the programmed cell death of T cells.
CAN008 is among the first batch of biopharmaceutical products in China to enter the Marketing Authorization Holder (MAH). Three early phase clinical studies have been conducted in Europe to assess the PK, safety, and efficacy of CAN008. A phase I study in Asian patients was completed as well. Safety and primary efficacy of CAN008 has been indicated in these early studies and phase II trials are currently underway in China.
Glioblastoma (GBM) is a Class IV glioma as classified by the World Health Organization. It is the most common primary intracranial tumor and the most invasive and highly malignant in nature. GBM can express CD95L, which is a key triggering factor for invasion and migration of GBM cells. Neutralization of CD95L can inhibit the migration and infiltration of glioblastoma cells, reduce the apoptosis of T cells induced by CD95L, and enhance immune recognition and destruction of GBM.